La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.43%688.872.6%$679.29m
MRNAModerna, Inc. 0.15%118.250.0%$616.94m
AMGNAmgen, Inc. -1.32%225.401.4%$605.62m
BIIBBiogen, Inc. 1.03%267.001.8%$554.62m
GILDGilead Sciences, Inc. -2.19%61.691.0%$514.54m
VRTXVertex Pharmaceuticals, Inc. -1.11%289.541.9%$401.56m
ILMNIllumina, Inc. -1.56%190.793.2%$338.76m
SNSSSunesis Pharmaceuticals, Inc. 4.40%4.270.7%$298.49m
SAVACassava Sciences, Inc. -2.90%41.820.0%$189.63m
BNTXBioNTech SE 0.96%134.880.0%$112.19m
NVAXNovavax, Inc. -1.99%18.2075.6%$84.03m
BMRNBioMarin Pharmaceutical, Inc. -0.34%84.774.2%$82.56m
NRBONeuroBo Pharmaceuticals, Inc. 9.35%13.690.0%$78.90m
PRTAProthena Corp. Plc 1.95%60.6313.8%$78.20m
CRSPCRISPR Therapeutics AG 1.33%65.350.6%$76.10m

Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.